Vifor Pharma Group has granted Japanese company Zeria Pharmaceutical exclusive rights to develop and commercialise Veltassa, its sodium-free potassium binder approved for the treatment of hyperkalaemia, in the third largest pharmaceutical market, Japan.
The collaboration with Zeria represents an important step in Vifor Pharma’s promise to produce Veltassa, Vifor said.
“Having Veltassa and Ferinject commercialised through the same partner represents a substantive step for Vifor Pharma in its goal towards expanding its cardio-renal network and becoming the global leader in cardio-renal therapies,” Vifor said in its press release
“We feel extremely fortunate that our trusted partner, Zeria, has chosen to further collaborate with us in offering this novel treatment to hyperkalaemia patients, including those on renin angiotensin aldosterone system inhibitor (RAASi) therapy. RAASi patients benefit in particular because Veltassa enables them to keep receiving an optimal dose of, and therefore the maximum live-saving benefit from, RAASi treatment,” said Stefan Schulze, President of the Executive Committee and COO of Vifor Pharma Group.